Central Nervous System: Our Commitment Never Stops

Central Nervous System (CNS) diseases, including schizophrenia, depression and Alzheimer’s disease, are a focus of Boehringer Ingelheim discovery research and development. We have several compounds in development, some in advanced clinical phases. Making progress is a challenge, and we may face setbacks along the way, but we remain hopeful that with time we can, and will, find effective solutions to devastating brain disorders. We have hope to transform lives of people living with brain disorders. Our Commitment Never Stops.